Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Spatial Features of Guselkumab Cutaneous Response
NCT05858632Phase 4
Key facts
- Status
- Recruiting
- Start
- Jul 2023
- Primary completion
- Jun 2028
- Countries
- 1
- Sponsor
- University of California, San Francisco
- Modality
- Monoclonal Antibodies
- Drugs
- guselkumab
- Conditions
- psoriasis
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in psoriasis, sponsored by University of California, San Francisco. Primary endpoint: Psoriasis Scalp Severity Index at 9 months. Started Jul 2023; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Guselkumab treatment
Guselkumab treatment for ~ 9 months
03
Who it enrols
Patients with moderate to severe scalp psoriasis (PSSI >= 12), excluding those who are pregnant, breastfeeding, have active infections, systemic malignancies, severe immunodeficiency, or have taken systemic immunosuppressives in the last 4 weeks.
04
Endpoints
Primary
Psoriasis Scalp Severity Index
Beyond the preview
Go deeper on NCT05858632.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858632.